manilatimes1d
TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of adult patients with moderately to severely active ulcerative colitis
Recommendation based on the findings from the Phase 3 QUASAR programme in ulcerative colitis 1. Beerse, Belgium (28 February 2025) - Johnson & Johnson today announced that the Com ...
manilatimes1d
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
Paul Goepfert, MD, Director for the Alabama Vaccine Research Clinic, stated: "I'm excited for the opportunity to follow-up on ...
Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45 th Annual Health Care Conference on March 4, ...
PMLiVE3d
J&J’s shares positive results for subcutaneous Tremfya in phase 3 ulcerative colitis trial
Johnson & Johnson (J&J) has shared positive results from a late-stage study evaluating a subcutaneous (SC) version of Tremfya ...
clinicaltrialsarena5d
OSE’s UC therapy prompts 16% clinical remission after ten weeks
The CoTikiS trial’s 10-week results from the 50-week ulcerative colitis trial saw as an endoscopic improvement rate of 32% in ...
Pharmabiz5d
J&J announces positive data from phase 3 ASTRO study of Tremfya SC induction therapy in adults with moderately to severely active ulcerative colitis
J&J announces positive data from phase 3 ASTRO study of Tremfya SC induction therapy in adults with moderately to severely active ulcerative colitis: Spring House, Pennsylvania Mo ...
Why Royalty Pharma Plc (RPRX) is the Best Performing Pharma Stock So Far in 2025
We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...
Hosted on MSN6d
Johnson & Johnson’s TREMFYA® Shows Promising Results in Ulcerative Colitis Patients
Johnson & Johnson (NYSE: JNJ) has announced positive results from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) ...
10 Best Performing Pharma Stocks So Far in 2025
In this article, we will look at the 10 Best Performing Pharma Stocks So Far in 2025. What’s Going on in the Pharma Sector?